Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174514 | 0.88 | GAA (0.46) | NR1H4NAMPTEPHX2MMP13MAPT | |
| SCHEMBL6177877 | 0.86 | MAPT (0.41) | NAMPTEPHX2MAPTLMNA | |
| SCHEMBL6700944 | 0.85 | ROCK2 (0.42) | NR1H4NAMPTEPHX2 | |
| SCHEMBL6175040 | 0.82 | GAA (0.50) | NAMPTMMP13MAPTLMNA | |
| SCHEMBL6176385 | 0.80 | MMP13 (0.46) | NR1H4EPHX2MMP13LMNA | |
| SCHEMBL6179339 | 0.74 | GAA (0.43) | NAMPTMMP13MAPTLMNA | |
| SCHEMBL10099566 | 0.74 | NR1H4 (0.69) | NR1H4EPHX2PTGER4PTGER2LMNA | |
| SCHEMBL5922862 | 0.72 | NPC1 (0.53) | NAMPTPTGER4MMP13MAPT | |
| SCHEMBL4438624 | 0.71 | KDM4E (0.41) | NAMPT | |
| SCHEMBL6697241 | 0.70 | LMNA (0.48) | NAMPTMMP13MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | NR1H4 1712/4885NAMPT 1755/4885EPHX2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.